Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
48 pending office actions • 33 art units • 46 examiners • 0 of 48 (0%) have an AI response strategy ready • 39 patents granted in the last 365 days
Oxford University Innovation Limited manages a portfolio with 45 pending office actions, primarily in the Biotechnology & Pharmaceuticals technology area. These 45 pending office actions are distributed among 43 distinct examiners. The count of 45 pending office actions is higher than the count of 43 distinct examiners, indicating a broad spread of the workload across many individuals.
The company's prosecution activity spans 31 distinct art units. This count of 31 distinct art units is lower than the 43 distinct examiners involved with the portfolio, showing a high degree of technical diversity. VASISTH, VISHAL V is the busiest examiner for the company, currently handling 2 pending office actions. This busiest examiner pending count of 2 is the highest for any single examiner in the current workload.
For practitioners, the 45 pending office actions across 31 distinct art units present a complex prosecution environment. The involvement of 43 distinct examiners means the company must adapt to a wide variety of individual examination styles. The busiest examiner pending count of 2 shows that even the most active examiner for the portfolio handles only a small portion of the total 45 pending office actions.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 9 (19%) |
| §103 only | 10 (21%) |
| §102 only | 3 (6%) |
| §112 only | 5 (10%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 4 (8%) |
| Multi-statute (no §101) | 15 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VASISTH, VISHAL V | 2 | 72.3% | +33.4% |
| BATES, KEENAN ALEXANDER | 2 | 45.5% | +79.5% |
| BALL, JOHN C | 1 | 78.8% | +16.2% |
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| CHOUDHURY, MUSTAK | 1 | 84.9% | +21.2% |
| KRETZER, CASEY L | 1 | 86.8% | +12.7% |
| ISMAIL, OMAR S | 1 | 91.2% | +10.0% |
| NEFF, MICHAEL R | 1 | 87.5% | +14.5% |
| MUTCHLER, CHRISTOPHER JOHN | 1 | 55.9% | +20.4% |
| PEDAPATI, CHANDHANA | 1 | 77.8% | +15.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18971420 | INTERFEROMETRIC SCATTERING MICROSCOPY | CHOUDHURY, MUSTAK | — |
| 18895587 | RADIOMIC SIGNATURE OF AN EPICARDIAL REGION | ISMAIL, OMAR S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624764 | METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | SPANGLER, JOSEPH RANKIN | 341d overdue |
| 18564140 | SYSTEM AND METHOD FOR STIMULATING A NERVE, AUTOMATED RESUSCITATION SYSTEM | HOUGH, JESSANDRA F | 42d overdue |
| 18279624 | BIOMARKER | COUNTS, GARY W | 19d overdue |
| 17781738 | INTRAORAL DEVICE | SHOSTAK, ANDREY | 10d overdue |
| 15963271 | DIAGNOSING MULTIPLE SCLEROSIS | DUNN, MCKENZIE A | 9d |
| 18272110 | CAVITATION AGENT | CABRAL, ROBERT S | 20d |
| 18727730 | DECOMPOSITION OF POLYOLEFINS | VASISTH, VISHAL V | 30d |
| 18039846 | OLIGONUCLEOTIDES | OLSON, ALEXANDRA NADINE | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18617722 | APPARATUS LOCALISATION | PEDAPATI, CHANDHANA | 15d |
| 18727730 | DECOMPOSITION OF POLYOLEFINS | VASISTH, VISHAL V | 30d |
| 19038507 | MOLECULAR HOPPER | BALL, JOHN C | — |
| 18996093 | LOADED EXTRACELLULAR VESICLE | RONEY, CELESTE A | — |
| 18971420 | INTERFEROMETRIC SCATTERING MICROSCOPY | CHOUDHURY, MUSTAK | — |
| 18867817 | FREE SPACE OPTICAL COMMUNICATIONS SYSTEM AND METHOD | KRETZER, CASEY L | — |
| 18895587 | RADIOMIC SIGNATURE OF AN EPICARDIAL REGION | ISMAIL, OMAR S | — |
| 18781133 | RADIOMIC SIGNATURE OF A PERIVASCULAR REGION | NEFF, MICHAEL R | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1771 | 2 |
| 3796 | 2 |
| 1678 | 2 |
| 1643 | 2 |
| 1684 | 2 |
| 1663 | 2 |
| 1612 | 1 |
| 2634 | 1 |
| 2635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19038507 | MOLECULAR HOPPER | BALL, JOHN C | — | DP | Non-Final OA | — | Pending | Jan 27, 2025 |
| 18996093 | LOADED EXTRACELLULAR VESICLE | RONEY, CELESTE A | 1612 | §103§112 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18971420 | INTERFEROMETRIC SCATTERING MICROSCOPY | CHOUDHURY, MUSTAK | — | §103Other | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18867817 | FREE SPACE OPTICAL COMMUNICATIONS SYSTEM AND METHOD | KRETZER, CASEY L | 2634 | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18895587 | RADIOMIC SIGNATURE OF AN EPICARDIAL REGION | ISMAIL, OMAR S | 2635 | §103 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18781133 | RADIOMIC SIGNATURE OF A PERIVASCULAR REGION | NEFF, MICHAEL R | — | §103§112 | Final Rejection | — | Pending | Jul 23, 2024 |
| 18727730 | DECOMPOSITION OF POLYOLEFINS | VASISTH, VISHAL V | 1771 | §103§112Other | Final Rejection | 30d | Pending | Jul 10, 2024 |
| 18727146 | DECOMPOSITION OF POLYOLEFINS | VASISTH, VISHAL V | 1771 | §102§103§112DP | Final Rejection | — | Pending | Jul 08, 2024 |
| 18709043 | SYSTEMS AND METHODS FOR MEASURING A RESPONSE OF A SUBJECT TO AN EVENT | MUTCHLER, CHRISTOPHER JOHN | 3796 | §101§112 | Final Rejection | — | Pending | May 10, 2024 |
| 18617722 | APPARATUS LOCALISATION | PEDAPATI, CHANDHANA | 2669 | §103 | Non-Final OA | 15d | Pending | Mar 27, 2024 |
| 18564140 | SYSTEM AND METHOD FOR STIMULATING A NERVE, AUTOMATED RESUSCITATION SYSTEM | HOUGH, JESSANDRA F | 3796 | §102§103 | Non-Final OA | 42d overdue | Pending | Nov 27, 2023 |
| 18563440 | ANTIBODIES | LIU, SUE XU | — | §102§103§112DP | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18558372 | POLYMERISATION OF PROPYLENE | BHUSHAN, KUMAR R | — | DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18556889 | HEALTH MONITORING OF ELECTROCHEMICAL ENERGY SUPPLY ELEMENTS | SINGLETARY, MICHAEL J | 2857 | §101§102§103 | Final Rejection | — | Pending | Oct 24, 2023 |
| 18555910 | METHOD AND COMPOSITION | SZPERKA, MICHAEL EDWARD | 1641 | §101§102§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18553295 | Gene Therapy for Retinal Disease | PAULUS, ERIN VIRGINIA | 1631 | §101§102 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18283103 | ENERGY CONVERTER | GORDON, BRYAN P | — | §102§103 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18282561 | MODULATING WAKEFULNESS AND AROUSAL | CAREY, MICHAEL JAMES | 3700 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18279624 | BIOMARKER | COUNTS, GARY W | 1678 | §101§102§112 | Final Rejection | 19d overdue | Pending | Aug 31, 2023 |
| 18451671 | DETECTION OF ACUTE MYELOID LEUKAEMIA | CHATTIN, AMY MARIE | 1643 | §102 | Final Rejection | — | Pending | Aug 17, 2023 |
| 18272110 | CAVITATION AGENT | CABRAL, ROBERT S | 1614 | §102§103§112Other | Final Rejection | 20d | Pending | Jul 13, 2023 |
| 18272115 | VACCINE COMPOSITIONS | GRIZER, CASSANDRA SENN | 1672 | §102§103§112 | Final Rejection | — | Pending | Jul 13, 2023 |
| 18272119 | IMMUNE MODULATING PARTICLES | LOVE, TREVOR M | 1611 | §102DP | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18272114 | TRANSDERMAL VACCINE | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18266179 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | SCHMITT, MICHAEL J | 1629 | §102 | Final Rejection | 28d | Pending | Jun 08, 2023 |
| 18039846 | OLIGONUCLEOTIDES | OLSON, ALEXANDRA NADINE | 1684 | §102§103§112Other | Non-Final OA | 33d | Pending | Jun 01, 2023 |
| 18021675 | METHOD OF MAKING RECOMBINANT AAVS | BATES, KEENAN ALEXANDER | 1631 | §103DP | Final Rejection | — | Pending | Feb 16, 2023 |
| 18021691 | PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | — | Pending | Feb 16, 2023 |
| 18010216 | ULTRASOUND-SENSITIVE BIODEGRADEABLE MULTI-CAVITY MICRO-PARTICLES | VU, JAKE MINH | 1618 | §102§103Other | Final Rejection | — | Pending | Dec 14, 2022 |
| 18057359 | EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES | HASAN, KHALEDA B | 1636 | §103§112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17999358 | ENHANCEMENT OF PRODUCTIVITY IN C3 PLANTS | STOCKDALE, JESSICA NICOLE | 1663 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 18, 2022 |
| 17924695 | CHIMAERIC PROTEINS AND THERAPEUTIC AGENTS | NATARAJAN, MEERA | 1643 | §112 | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17924425 | POLYNUCLEOTIDE ARRAYS | ZHANG, KAIJIANG | 1684 | §102 | Final Rejection | 30d overdue | Pending | Nov 10, 2022 |
| 17920561 | METHOD OF REDUCING AND RECYCLING OXIDIZED FLAVIN COFACTORS | BOWERS, ERIN M | 1653 | §103 | Final Rejection | 80d overdue | Pending | Oct 21, 2022 |
| 17914936 | METHOD FOR FORMING COATED HYDROGEL BEADS | WASHVILLE, JEFFREY D | 1766 | §102§103 | Final Rejection | 36d | Pending | Sep 27, 2022 |
| 17796334 | DNA Amplification Method | JOHNSON, ALLISON MARIE | 1638 | §112 | Final Rejection | 45d overdue | Pending | Jul 29, 2022 |
| 17796303 | Process for Making Adenoassociated Viral Vectors | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112 | Non-Final OA | — | Pending | Jul 29, 2022 |
| 17781738 | INTRAORAL DEVICE | SHOSTAK, ANDREY | 3791 | §103§112Other | Non-Final OA | 10d overdue | Pending | Jun 02, 2022 |
| 17773907 | Identification and Characterisation of Herbicides and Plant Growth Regulators | SANFORD, DIANA PATRICIA | 1687 | §101§112 | Non-Final OA | — | Pending | May 03, 2022 |
| 17762823 | BIOREACTOR CHAMBER | LOPEZLIRA, ASHLEY NICOLE | 1799 | §103 | Non-Final OA | — | Pending | Mar 23, 2022 |
| 17642968 | SELECTIVE REMOVAL OF CHARGED SPECIES | PEO, JONATHAN M | 1779 | §103 | Final Rejection | — | Pending | Mar 15, 2022 |
| 17629593 | Modified Plants | MCWILLIAMS, KELSEY LYNN | 1663 | §112 | Final Rejection | — | Pending | Jan 24, 2022 |
| 17626833 | PROCESS FOR PRODUCING A GASEOUS PRODUCT COMPRISING HYDROGEN | DOWNES, NATHANAEL JASON | 1794 | §103 | Final Rejection | 73d overdue | Pending | Jan 13, 2022 |
| 17624764 | METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | SPANGLER, JOSEPH RANKIN | 1656 | §101§103§112 | Final Rejection | 341d overdue | Pending | Jan 04, 2022 |
| 17618648 | OPTICAL DEVICES AND METHODS | TAVLYKAEV, ROBERT FUATOVICH | 2896 | §103 | Non-Final OA | — | Pending | Dec 13, 2021 |
| 17599616 | UNIVERSAL DNA ASSEMBLY | RYAN, DOUGLAS CHARLES | 1635 | §101§102§112 | Non-Final OA | — | Pending | Sep 29, 2021 |
| 17278679 | EDITING OF HAEMOGLOBIN GENES | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103Other | Final Rejection | — | Pending | Mar 23, 2021 |
| 15963271 | DIAGNOSING MULTIPLE SCLEROSIS | DUNN, MCKENZIE A | 1678 | §103§112 | Final Rejection | 9d | Pending | Apr 26, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial